Kinga Nowicka is a CMC process development leader with deep expertise in Cell and Gene Therapy. She currently serves as Head of Viral Vectors at NecstGen in Leiden, where she directs end-to-end development, scale-up, and GMP tech transfer of viral vector manufacturing platforms. Prior to this role, she spearheaded process innovation at King’s College London’s Gene Therapy Innovation Hub, embedding sustainable practices into advanced therapy development. Kinga built a strong track record at Autolus Therapeutics, advancing from Research Scientist to Associate Director, where she drove viral vector strategy, regulatory submissions, and cross-functional leadership initiatives. She began her career at Oxford BioMedica, contributing to upstream and analytical process development that enabled scalable gene therapy manufacturing solutions. Her technical portfolio spans upstream and downstream viral vector optimization, analytical method development, and regulatory CMC authorship. Passionate about innovation and organizational impact, she is pursuing an MBA at Imperial College Business School to complement her scientific leadership with strategic and financial acumen. She is recognized for her ability to align cutting-edge bioprocessing with business critical outcomes, positioning her at the intersection of science, strategy, and execution.